Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an UpdateAlbendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
- Authors
- 채종일; 정봉광; 홍성종
- Issue Date
- Jun-2021
- Publisher
- 대한기생충학ㆍ열대의학회
- Keywords
- Albendazole; mebendazole; nematode; trematode; cestode; liver toxicity; drug resistance; anti-cancer activity; review
- Citation
- The Korean Journal of Parasitology, v.59, no.3, pp 189 - 225
- Pages
- 37
- Journal Title
- The Korean Journal of Parasitology
- Volume
- 59
- Number
- 3
- Start Page
- 189
- End Page
- 225
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/50093
- DOI
- 10.3347/kjp.2021.59.3.189
- ISSN
- 0023-4001
1738-0006
- Abstract
- The use of albendazole and mebendazole, i.e., benzimidazole broad-spectrum anthelmintics, in treatment of parasitic infections, as well as cancers, is briefly reviewed. These drugs are known to block the microtubule systems of parasites and mammalian cells leading to inhibition of glucose uptake and transport and finally cell death. Eventually they exhibit ovicidal, larvicidal, and vermicidal effects on parasites, and tumoricidal effects on hosts. Albendazole and meben- dazole are most frequently prescribed for treatment of intestinal nematode infections (ascariasis, hookworm infections, trichuriasis, strongyloidiasis, and enterobiasis) and can also be used for intestinal tapeworm infections (taeniases and hy- menolepiasis). However, these drugs also exhibit considerable therapeutic effects against tissue nematode/cestode infec- tions (visceral, ocular, neural, and cutaneous larva migrans, anisakiasis, trichinosis, hepatic and intestinal capillariasis, an- giostrongyliasis, gnathostomiasis, gongylonemiasis, thelaziasis, dracunculiasis, cerebral and subcutaneous cysticercosis, and echinococcosis). Albendazole is also used for treatment of filarial infections (lymphatic filariasis, onchocerciasis, loia- sis, mansonellosis, and dirofilariasis) alone or in combination with other drugs, such as ivermectin or diethylcarbamazine. Albendazole was tried even for treatment of trematode (fascioliasis, clonorchiasis, opisthorchiasis, and intestinal fluke in- fections) and protozoan infections (giardiasis, vaginal trichomoniasis, cryptosporidiosis, and microsporidiosis). These drugs are generally safe with few side effects; however, when they are used for prolonged time (>14-28 days) or even only 1 time, liver toxicity and other side reactions may occur. In hookworms, Trichuris trichiura, possibly Ascaris lumbricoi- des, Wuchereria bancrofti, and Giardia sp., there are emerging issues of drug resistance. It is of particular note that alben- dazole and mebendazole have been repositioned as promising anti-cancer drugs. These drugs have been shown to be active in vitro and in vivo (animals) against liver, lung, ovary, prostate, colorectal, breast, head and neck cancers, and mel- anoma. Two clinical reports for albendazole and 2 case reports for mebendazole have revealed promising effects of these drugs in human patients having variable types of cancers. However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popu- larly used than albendazole in anti-cancer clinical trials.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/50093)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.